Spirocyclic inhibitors of hepatitis B virus

A compound of general formula (I):

• wherein:
• Cy is aryl or heteroaryl;
• each of m and n is independently 1 or 2;
• R1 is H, F, Br, Cl or CH3;
• R2 is selected from the group consisting of:
• 5 or 6 membered heteroaryl ring optionally substituted with one or more substituents each independently selected from the group consisting of:
• OH, halogen, CN, C1-6alkyl, hydroxyC1-6alkyl, haloC1-6alkyl, haloC1-6alkoxy, C1-6alkoxy and NH2;
• haloC1-4alkyl;
• and
• C(═O)NR3R4;
• each of R3 and R4 is independently selected from the group consisting of:
• hydrogen;
• C1-3alkyl;
• haloC1-4alkyl;
• and
• C3-5-cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of:
• methyl, F, Cl, CHF2 and CF3;
• or R3 and R4 form together with the nitrogen atom to which they are attached a cyclic amine selected from the group consisting of:
• aziridine, azetidine, pyrrolidine, piperidine, morpholine and thiomorpholine each of said cyclic amine being optionally substituted with one or more substituents each independently selected from the group consisting of:
• methyl, fluorine, CHF2 and CF3;
• Ra, Rb, Rc and Rd are each independently selected from the group consisting of:
• hydrogen, halogen, methyl, CN, CHF2 and CF3;
• or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.